Voices: Kuehn

The Joy of Capital Spending

India’s Top 20 Pharma companies are upgrading facilities to proactively enjoy Pharma market opportunities

By Steven Kuehn, Editor in Chief
Sep 30, 2015

India’s top 20 pharmaceutical companies are increasing capital expenditures by 40 percent to take advantage of market opportunities to come, says a report from CRISIL, a global analytical company providing ratings, research, risk and policy advisory services. The article, which appeared on The Economic Times of India website, attributes the CapEx increase in India to the fact that the country’s “drug makers are expected to pay greater attention to regulated markets, especially the U.S. market, and to take advantage of substantial patent expiries expected in the medium term, as well as an ever-increasing demand for generics.”

Read More